We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
SuperGen Announces Identification of new Class of Etk/Bmx Kinase Inhibitors at the AACR 100th Annual Meeting 2009
News

SuperGen Announces Identification of new Class of Etk/Bmx Kinase Inhibitors at the AACR 100th Annual Meeting 2009

SuperGen Announces Identification of new Class of Etk/Bmx Kinase Inhibitors at the AACR 100th Annual Meeting 2009
News

SuperGen Announces Identification of new Class of Etk/Bmx Kinase Inhibitors at the AACR 100th Annual Meeting 2009

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "SuperGen Announces Identification of new Class of Etk/Bmx Kinase Inhibitors at the AACR 100th Annual Meeting 2009"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

SuperGen Inc. has announced as part of a series of presentations at the 100th Annual Meeting of the American Association for Cancer Research (AACR), that it has identified a new class of small molecules which successfully inhibit Etk/Bmx kinase in preclinical cancer models.

Entitled, “Targeting Etk/Bmx kinase with small molecule inhibitors,” the poster highlights data indicating that SuperGen lead compounds in this class inhibit the autophosphorylation of Etk, the activation of STAT3 downstream of EGF stimulation, and inhibit the colony formation of prostate and liver cancer cells lines in soft agar.

“SuperGen is committed to bringing first in class drugs into the clinic against cancer drug targets, and Etk/Bmx represents another one of these targets,” said Dr. David Bearss, SuperGen’s Chief Scientific Officer. “We are excited about selecting a clinical candidate for this program and think this program signifies another example of what our company and drug discovery technology can accomplish.”
Advertisement